UroGen Pharma Ltd. (URGN)

UroGen Pharma: An Emerging GARP Stock

Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to Analysts

Here's Why You Should Add URGN Stock to Your Portfolio Now

Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN)

Urogen Pharma: Upside After Bladder Cancer Launch

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Urogen Pharma Q2 Earnings Call Highlights

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

ADAR1 Capital Management LLC Boosts Stock Position in Urogen Pharma $URGN